| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcohol Drinking | 119 | 2025 | 4045 | 11.860 |
Why?
|
| Fatty Acids, Nonesterified | 22 | 2023 | 393 | 6.130 |
Why?
|
| Hip Fractures | 21 | 2024 | 996 | 5.430 |
Why?
|
| Hypotension, Orthostatic | 11 | 2023 | 258 | 4.330 |
Why?
|
| Coronary Disease | 49 | 2023 | 5915 | 4.010 |
Why?
|
| Hypertension | 51 | 2024 | 8616 | 3.690 |
Why?
|
| Cardiovascular Diseases | 90 | 2024 | 15657 | 3.610 |
Why?
|
| Aged | 366 | 2025 | 171343 | 2.800 |
Why?
|
| Osteoporotic Fractures | 8 | 2024 | 415 | 2.680 |
Why?
|
| Peripheral Arterial Disease | 16 | 2023 | 1304 | 2.650 |
Why?
|
| Insulin Resistance | 27 | 2023 | 3989 | 2.600 |
Why?
|
| Myocardial Infarction | 64 | 2024 | 11513 | 2.560 |
Why?
|
| Risk Factors | 258 | 2024 | 74881 | 2.560 |
Why?
|
| Procollagen | 8 | 2015 | 189 | 2.510 |
Why?
|
| Antihypertensive Agents | 16 | 2024 | 2030 | 2.420 |
Why?
|
| Diabetes Mellitus | 32 | 2022 | 5887 | 2.100 |
Why?
|
| Male | 425 | 2024 | 364142 | 2.100 |
Why?
|
| Behavioral Risk Factor Surveillance System | 10 | 2024 | 212 | 2.100 |
Why?
|
| Prospective Studies | 170 | 2024 | 54871 | 2.010 |
Why?
|
| Peptide Fragments | 16 | 2023 | 5143 | 1.990 |
Why?
|
| Female | 426 | 2025 | 396520 | 1.950 |
Why?
|
| Blood Glucose | 34 | 2023 | 6422 | 1.930 |
Why?
|
| Humans | 561 | 2025 | 766766 | 1.880 |
Why?
|
| Incidence | 96 | 2024 | 21525 | 1.840 |
Why?
|
| Dihydrotestosterone | 4 | 2022 | 194 | 1.830 |
Why?
|
| Atrial Fibrillation | 24 | 2024 | 5182 | 1.820 |
Why?
|
| Dementia | 15 | 2024 | 2741 | 1.760 |
Why?
|
| Blood Pressure | 38 | 2024 | 8533 | 1.760 |
Why?
|
| United States | 163 | 2024 | 72951 | 1.750 |
Why?
|
| Ethanol | 11 | 2019 | 1326 | 1.680 |
Why?
|
| Proportional Hazards Models | 81 | 2024 | 12534 | 1.680 |
Why?
|
| Middle Aged | 272 | 2025 | 223257 | 1.640 |
Why?
|
| Aged, 80 and over | 131 | 2024 | 59550 | 1.630 |
Why?
|
| Heart Failure | 36 | 2023 | 11882 | 1.580 |
Why?
|
| Cardiovascular System | 7 | 2024 | 839 | 1.570 |
Why?
|
| Diabetes Mellitus, Type 2 | 41 | 2024 | 12245 | 1.540 |
Why?
|
| Fatty Acid-Binding Proteins | 5 | 2020 | 292 | 1.510 |
Why?
|
| Bone Density | 13 | 2024 | 3491 | 1.500 |
Why?
|
| Influenza Vaccines | 4 | 2022 | 780 | 1.450 |
Why?
|
| Risk Assessment | 61 | 2024 | 24295 | 1.430 |
Why?
|
| Brachial Artery | 4 | 2021 | 373 | 1.410 |
Why?
|
| Atherosclerosis | 18 | 2023 | 3420 | 1.400 |
Why?
|
| Mobility Limitation | 4 | 2023 | 409 | 1.390 |
Why?
|
| Blood Pressure Determination | 10 | 2024 | 646 | 1.390 |
Why?
|
| Lysine | 5 | 2019 | 997 | 1.340 |
Why?
|
| Fasting | 14 | 2022 | 1609 | 1.330 |
Why?
|
| Alcoholic Beverages | 12 | 2023 | 266 | 1.320 |
Why?
|
| Apolipoproteins | 4 | 2022 | 328 | 1.310 |
Why?
|
| Kidney Failure, Chronic | 10 | 2022 | 2505 | 1.300 |
Why?
|
| Catechol O-Methyltransferase | 4 | 2019 | 250 | 1.290 |
Why?
|
| C-Reactive Protein | 18 | 2023 | 3853 | 1.270 |
Why?
|
| Natriuretic Peptide, Brain | 10 | 2023 | 1750 | 1.270 |
Why?
|
| Health Surveys | 22 | 2021 | 4055 | 1.260 |
Why?
|
| Cross-Sectional Studies | 66 | 2024 | 26310 | 1.250 |
Why?
|
| Hospitalization | 19 | 2021 | 10823 | 1.250 |
Why?
|
| Nutrition Surveys | 15 | 2024 | 1737 | 1.240 |
Why?
|
| Coffee | 6 | 2020 | 594 | 1.230 |
Why?
|
| Transforming Growth Factor beta | 6 | 2017 | 1996 | 1.230 |
Why?
|
| Longitudinal Studies | 54 | 2024 | 14762 | 1.210 |
Why?
|
| Disabled Persons | 4 | 2023 | 1208 | 1.210 |
Why?
|
| Follow-Up Studies | 85 | 2024 | 39309 | 1.200 |
Why?
|
| Albuminuria | 8 | 2024 | 659 | 1.160 |
Why?
|
| Diet, Sodium-Restricted | 4 | 2023 | 291 | 1.150 |
Why?
|
| Beer | 6 | 2024 | 135 | 1.120 |
Why?
|
| Life Style | 24 | 2019 | 3926 | 1.120 |
Why?
|
| Stroke | 31 | 2024 | 9741 | 1.110 |
Why?
|
| Adult | 181 | 2024 | 223307 | 1.080 |
Why?
|
| Suicide | 11 | 2016 | 1606 | 1.080 |
Why?
|
| Hemoglobins | 4 | 2024 | 1531 | 1.070 |
Why?
|
| Adiponectin | 10 | 2023 | 1121 | 1.060 |
Why?
|
| Exercise | 13 | 2024 | 5945 | 1.060 |
Why?
|
| Academic Medical Centers | 8 | 2019 | 2783 | 1.050 |
Why?
|
| Body Mass Index | 38 | 2024 | 13050 | 1.040 |
Why?
|
| Activities of Daily Living | 7 | 2023 | 2429 | 1.020 |
Why?
|
| Independent Living | 9 | 2022 | 584 | 1.020 |
Why?
|
| Heart Rate | 6 | 2022 | 4207 | 1.000 |
Why?
|
| Ankle Brachial Index | 11 | 2023 | 163 | 1.000 |
Why?
|
| Body Height | 6 | 2016 | 1562 | 1.000 |
Why?
|
| Creatinine | 8 | 2021 | 1917 | 0.990 |
Why?
|
| Sex Hormone-Binding Globulin | 5 | 2025 | 557 | 0.970 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 4 | 2016 | 127 | 0.970 |
Why?
|
| Glomerular Filtration Rate | 12 | 2021 | 2232 | 0.950 |
Why?
|
| Lipoproteins, HDL | 9 | 2023 | 677 | 0.950 |
Why?
|
| Cohort Studies | 68 | 2024 | 41710 | 0.940 |
Why?
|
| Mendelian Randomization Analysis | 4 | 2020 | 1044 | 0.940 |
Why?
|
| Prevalence | 43 | 2021 | 15835 | 0.920 |
Why?
|
| American Cancer Society | 1 | 2024 | 69 | 0.920 |
Why?
|
| Health Behavior | 11 | 2022 | 2649 | 0.920 |
Why?
|
| Coronary Artery Disease | 19 | 2022 | 6558 | 0.910 |
Why?
|
| Protein Precursors | 3 | 2020 | 1134 | 0.910 |
Why?
|
| Renal Insufficiency, Chronic | 11 | 2024 | 2306 | 0.900 |
Why?
|
| Polymorphism, Single Nucleotide | 30 | 2024 | 16044 | 0.890 |
Why?
|
| Cause of Death | 23 | 2024 | 3716 | 0.890 |
Why?
|
| Cross-Over Studies | 7 | 2025 | 2108 | 0.880 |
Why?
|
| Norway | 13 | 2024 | 500 | 0.860 |
Why?
|
| Prognosis | 52 | 2024 | 29948 | 0.850 |
Why?
|
| Insulin | 22 | 2023 | 6608 | 0.840 |
Why?
|
| Fibroblast Growth Factors | 8 | 2017 | 871 | 0.840 |
Why?
|
| Health Status Indicators | 3 | 2018 | 968 | 0.840 |
Why?
|
| Magnesium | 7 | 2014 | 815 | 0.830 |
Why?
|
| Fatty Acids | 10 | 2023 | 1806 | 0.830 |
Why?
|
| Multivariate Analysis | 32 | 2024 | 12064 | 0.820 |
Why?
|
| Dietary Fats | 4 | 2023 | 2001 | 0.810 |
Why?
|
| Tea | 5 | 2011 | 289 | 0.810 |
Why?
|
| Continuity of Patient Care | 3 | 2014 | 1077 | 0.800 |
Why?
|
| Lipoproteins | 4 | 2022 | 871 | 0.800 |
Why?
|
| Influenza, Human | 3 | 2022 | 1543 | 0.790 |
Why?
|
| Hypercholesterolemia | 6 | 2022 | 1145 | 0.790 |
Why?
|
| Cystatin C | 6 | 2021 | 272 | 0.780 |
Why?
|
| Age Factors | 33 | 2024 | 18397 | 0.780 |
Why?
|
| Resistance Training | 2 | 2014 | 197 | 0.780 |
Why?
|
| Physical Fitness | 2 | 2018 | 743 | 0.780 |
Why?
|
| Taxes | 1 | 2024 | 219 | 0.770 |
Why?
|
| Vascular Diseases | 6 | 2024 | 1161 | 0.770 |
Why?
|
| Liver Cirrhosis | 7 | 2021 | 1960 | 0.770 |
Why?
|
| Cholesterol, HDL | 15 | 2023 | 1812 | 0.760 |
Why?
|
| Coronary Artery Bypass | 8 | 2009 | 2188 | 0.760 |
Why?
|
| Time Factors | 50 | 2024 | 40149 | 0.760 |
Why?
|
| Fatty Acids, Omega-3 | 5 | 2021 | 1399 | 0.750 |
Why?
|
| Outpatient Clinics, Hospital | 2 | 2013 | 392 | 0.750 |
Why?
|
| Apolipoprotein C-III | 5 | 2022 | 209 | 0.740 |
Why?
|
| Obesity | 29 | 2023 | 13090 | 0.730 |
Why?
|
| Lead | 6 | 2024 | 879 | 0.730 |
Why?
|
| Sex Factors | 20 | 2019 | 10619 | 0.720 |
Why?
|
| Metals, Heavy | 1 | 2022 | 149 | 0.720 |
Why?
|
| Aromatase Inhibitors | 1 | 2025 | 519 | 0.720 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2025 | 706 | 0.710 |
Why?
|
| Clinical Enzyme Tests | 2 | 2019 | 114 | 0.710 |
Why?
|
| Vitamin D Deficiency | 3 | 2014 | 1349 | 0.700 |
Why?
|
| Length of Stay | 5 | 2019 | 6490 | 0.690 |
Why?
|
| Diet | 19 | 2024 | 8088 | 0.690 |
Why?
|
| Retinal Diseases | 3 | 2024 | 709 | 0.690 |
Why?
|
| Guideline Adherence | 4 | 2024 | 2234 | 0.680 |
Why?
|
| Diabetes Complications | 6 | 2015 | 1319 | 0.680 |
Why?
|
| Kidney Diseases | 6 | 2019 | 2101 | 0.670 |
Why?
|
| Periodontitis | 3 | 2017 | 576 | 0.660 |
Why?
|
| Patient Discharge | 8 | 2018 | 3465 | 0.660 |
Why?
|
| Accidental Falls | 5 | 2023 | 1078 | 0.650 |
Why?
|
| Hospitalists | 2 | 2013 | 297 | 0.650 |
Why?
|
| Acute Coronary Syndrome | 2 | 2024 | 2186 | 0.640 |
Why?
|
| Body Composition | 4 | 2021 | 2441 | 0.640 |
Why?
|
| Apolipoproteins E | 8 | 2022 | 1459 | 0.640 |
Why?
|
| Odds Ratio | 21 | 2021 | 9661 | 0.640 |
Why?
|
| Carotid Artery Diseases | 4 | 2018 | 872 | 0.640 |
Why?
|
| Vasodilation | 2 | 2021 | 969 | 0.630 |
Why?
|
| Intermittent Claudication | 2 | 2014 | 305 | 0.630 |
Why?
|
| Parity | 5 | 2024 | 931 | 0.630 |
Why?
|
| Fibrosis | 6 | 2015 | 2077 | 0.630 |
Why?
|
| Lipoproteins, VLDL | 3 | 2018 | 198 | 0.630 |
Why?
|
| Health Services Accessibility | 4 | 2022 | 5514 | 0.620 |
Why?
|
| Lovastatin | 3 | 2008 | 114 | 0.620 |
Why?
|
| Body Size | 1 | 2021 | 461 | 0.610 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2022 | 2143 | 0.610 |
Why?
|
| Aging | 16 | 2023 | 8731 | 0.610 |
Why?
|
| Testosterone | 3 | 2022 | 2495 | 0.610 |
Why?
|
| Muscular Atrophy | 1 | 2021 | 335 | 0.610 |
Why?
|
| Logistic Models | 26 | 2021 | 13278 | 0.610 |
Why?
|
| Genetic Pleiotropy | 1 | 2019 | 182 | 0.610 |
Why?
|
| Wine | 6 | 2025 | 172 | 0.610 |
Why?
|
| Heart Diseases | 5 | 2021 | 2817 | 0.600 |
Why?
|
| Blood Flow Velocity | 2 | 2020 | 1374 | 0.600 |
Why?
|
| Troponin I | 3 | 2023 | 659 | 0.600 |
Why?
|
| Mortality | 8 | 2021 | 2910 | 0.600 |
Why?
|
| Erythropoietin | 1 | 2022 | 718 | 0.600 |
Why?
|
| Absorptiometry, Photon | 8 | 2021 | 1707 | 0.600 |
Why?
|
| Resuscitation Orders | 1 | 2020 | 271 | 0.600 |
Why?
|
| Chronic Disease | 7 | 2023 | 9357 | 0.600 |
Why?
|
| Aspirin | 5 | 2017 | 3135 | 0.590 |
Why?
|
| Feeding Behavior | 14 | 2022 | 3208 | 0.590 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2017 | 982 | 0.590 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2018 | 52 | 0.590 |
Why?
|
| Community-Acquired Infections | 3 | 2013 | 470 | 0.590 |
Why?
|
| Linear Models | 18 | 2021 | 5874 | 0.580 |
Why?
|
| Nutrition Policy | 4 | 2024 | 467 | 0.580 |
Why?
|
| Legal Guardians | 1 | 2018 | 59 | 0.580 |
Why?
|
| Risk | 26 | 2020 | 9602 | 0.580 |
Why?
|
| Ventricular Function, Left | 9 | 2023 | 3935 | 0.580 |
Why?
|
| Diet, Fat-Restricted | 1 | 2020 | 328 | 0.580 |
Why?
|
| Fatty Acids, Monounsaturated | 5 | 2023 | 190 | 0.580 |
Why?
|
| Vitamin K | 3 | 2016 | 314 | 0.570 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2016 | 157 | 0.570 |
Why?
|
| Heart Ventricles | 6 | 2018 | 3832 | 0.560 |
Why?
|
| Dizziness | 1 | 2020 | 269 | 0.560 |
Why?
|
| Fractures, Bone | 4 | 2023 | 2043 | 0.560 |
Why?
|
| Electrocardiography | 10 | 2023 | 6408 | 0.560 |
Why?
|
| Health Status | 9 | 2014 | 4087 | 0.550 |
Why?
|
| Fibrinogen | 7 | 2024 | 893 | 0.550 |
Why?
|
| Homocysteine | 3 | 2015 | 638 | 0.550 |
Why?
|
| Quality of Life | 8 | 2020 | 13476 | 0.550 |
Why?
|
| Healthcare Disparities | 4 | 2020 | 3411 | 0.550 |
Why?
|
| Geriatric Assessment | 4 | 2020 | 1422 | 0.540 |
Why?
|
| Renal Dialysis | 5 | 2024 | 1790 | 0.540 |
Why?
|
| Case-Control Studies | 36 | 2021 | 22248 | 0.530 |
Why?
|
| Cerebral Infarction | 2 | 2017 | 968 | 0.530 |
Why?
|
| Smoking | 24 | 2024 | 9077 | 0.530 |
Why?
|
| Phospholipids | 7 | 2021 | 778 | 0.530 |
Why?
|
| Syncope | 1 | 2019 | 431 | 0.530 |
Why?
|
| Exercise Test | 3 | 2021 | 2188 | 0.530 |
Why?
|
| Chest Pain | 2 | 2019 | 1101 | 0.530 |
Why?
|
| Prostatic Hyperplasia | 1 | 2020 | 514 | 0.520 |
Why?
|
| Women's Health | 3 | 2024 | 2081 | 0.520 |
Why?
|
| Brain Chemistry | 1 | 2020 | 951 | 0.520 |
Why?
|
| Leukoaraiosis | 1 | 2017 | 114 | 0.520 |
Why?
|
| Potassium | 3 | 2016 | 1314 | 0.520 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 3236 | 0.520 |
Why?
|
| Heroin Dependence | 1 | 2017 | 173 | 0.520 |
Why?
|
| Ambulatory Care | 3 | 2016 | 2779 | 0.520 |
Why?
|
| Posture | 2 | 2023 | 955 | 0.520 |
Why?
|
| Hospital Charges | 1 | 2018 | 345 | 0.510 |
Why?
|
| Postmenopause | 1 | 2025 | 2517 | 0.500 |
Why?
|
| Marijuana Smoking | 3 | 2024 | 261 | 0.500 |
Why?
|
| Clonidine | 1 | 2016 | 170 | 0.500 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2016 | 92 | 0.500 |
Why?
|
| Physical Exertion | 2 | 2012 | 667 | 0.490 |
Why?
|
| Genetic Loci | 8 | 2024 | 2630 | 0.490 |
Why?
|
| Cognition | 7 | 2022 | 7057 | 0.490 |
Why?
|
| Amlodipine | 3 | 2020 | 84 | 0.480 |
Why?
|
| Critical Illness | 7 | 2020 | 2750 | 0.480 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2016 | 217 | 0.470 |
Why?
|
| Triglycerides | 6 | 2022 | 2441 | 0.470 |
Why?
|
| Vaccination | 3 | 2022 | 3434 | 0.460 |
Why?
|
| Genotype | 24 | 2019 | 13036 | 0.460 |
Why?
|
| Betaine | 1 | 2014 | 90 | 0.450 |
Why?
|
| Physical Endurance | 1 | 2016 | 369 | 0.440 |
Why?
|
| Hydroxycholecalciferols | 1 | 2013 | 44 | 0.440 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 2015 | 222 | 0.430 |
Why?
|
| Glucose | 9 | 2023 | 4340 | 0.430 |
Why?
|
| beta 2-Microglobulin | 1 | 2014 | 330 | 0.430 |
Why?
|
| Ultrasonography | 7 | 2021 | 5992 | 0.430 |
Why?
|
| Docosahexaenoic Acids | 3 | 2017 | 915 | 0.430 |
Why?
|
| National Institute on Alcohol Abuse and Alcoholism (U.S.) | 1 | 2013 | 10 | 0.430 |
Why?
|
| Lipids | 12 | 2023 | 3319 | 0.420 |
Why?
|
| Leukoencephalopathies | 1 | 2016 | 258 | 0.420 |
Why?
|
| Socioeconomic Factors | 13 | 2024 | 7841 | 0.420 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2015 | 1567 | 0.420 |
Why?
|
| Gout | 1 | 2020 | 622 | 0.420 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2014 | 1805 | 0.420 |
Why?
|
| Inpatients | 2 | 2018 | 2565 | 0.420 |
Why?
|
| Overweight | 6 | 2023 | 2446 | 0.410 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2024 | 4349 | 0.410 |
Why?
|
| Triage | 1 | 2019 | 995 | 0.410 |
Why?
|
| Health Personnel | 6 | 2019 | 3384 | 0.410 |
Why?
|
| Choline | 1 | 2014 | 511 | 0.400 |
Why?
|
| Proton Pump Inhibitors | 3 | 2019 | 550 | 0.390 |
Why?
|
| Genetic Predisposition to Disease | 15 | 2024 | 18075 | 0.390 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2016 | 2270 | 0.390 |
Why?
|
| Genetic Variation | 7 | 2019 | 6612 | 0.390 |
Why?
|
| Brain Ischemia | 9 | 2021 | 3001 | 0.390 |
Why?
|
| Intermediate Filaments | 2 | 2023 | 171 | 0.390 |
Why?
|
| Microcirculation | 2 | 2016 | 1282 | 0.390 |
Why?
|
| Vitamin B Complex | 1 | 2014 | 299 | 0.390 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2014 | 113 | 0.390 |
Why?
|
| Myocardial Ischemia | 3 | 2016 | 2132 | 0.390 |
Why?
|
| Beverages | 4 | 2017 | 819 | 0.380 |
Why?
|
| Genome-Wide Association Study | 17 | 2024 | 12806 | 0.380 |
Why?
|
| Medicare | 10 | 2020 | 6820 | 0.380 |
Why?
|
| Colorectal Neoplasms | 3 | 2024 | 6962 | 0.380 |
Why?
|
| Insurance, Health | 3 | 2019 | 2520 | 0.380 |
Why?
|
| Medicaid | 2 | 2022 | 2836 | 0.380 |
Why?
|
| Heterozygote | 2 | 2015 | 2795 | 0.380 |
Why?
|
| Alcohol-Related Disorders | 2 | 2018 | 243 | 0.380 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2016 | 361 | 0.380 |
Why?
|
| Endonucleases | 1 | 2014 | 371 | 0.380 |
Why?
|
| Trans Fatty Acids | 3 | 2021 | 155 | 0.370 |
Why?
|
| Cardiology | 1 | 2022 | 1701 | 0.370 |
Why?
|
| Glucose Tolerance Test | 5 | 2018 | 1180 | 0.370 |
Why?
|
| Breast Neoplasms | 4 | 2025 | 21162 | 0.360 |
Why?
|
| Critical Care | 2 | 2020 | 2714 | 0.360 |
Why?
|
| Acute Kidney Injury | 4 | 2020 | 1946 | 0.360 |
Why?
|
| Inflammation | 11 | 2023 | 10860 | 0.350 |
Why?
|
| Hemostatics | 3 | 2024 | 247 | 0.350 |
Why?
|
| Sweden | 11 | 2024 | 1382 | 0.350 |
Why?
|
| Depression | 7 | 2022 | 8228 | 0.350 |
Why?
|
| Chlorthalidone | 2 | 2020 | 21 | 0.340 |
Why?
|
| Micronutrients | 1 | 2013 | 390 | 0.340 |
Why?
|
| Weight Loss | 5 | 2022 | 2712 | 0.340 |
Why?
|
| Survivors | 6 | 2014 | 2379 | 0.340 |
Why?
|
| Carotid Stenosis | 1 | 2017 | 858 | 0.340 |
Why?
|
| Pneumonia | 3 | 2013 | 2159 | 0.340 |
Why?
|
| Models, Genetic | 1 | 2020 | 3450 | 0.340 |
Why?
|
| Comorbidity | 16 | 2023 | 10580 | 0.340 |
Why?
|
| Drinking Behavior | 3 | 2019 | 102 | 0.340 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 637 | 0.340 |
Why?
|
| Patient Readmission | 2 | 2014 | 3283 | 0.340 |
Why?
|
| Pacemaker, Artificial | 1 | 2016 | 828 | 0.340 |
Why?
|
| Cholesterol, Dietary | 1 | 2010 | 224 | 0.340 |
Why?
|
| Predictive Value of Tests | 16 | 2024 | 15416 | 0.330 |
Why?
|
| Atenolol | 2 | 2020 | 99 | 0.330 |
Why?
|
| Calcinosis | 2 | 2016 | 1480 | 0.330 |
Why?
|
| Liver | 5 | 2021 | 7571 | 0.330 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2019 | 1514 | 0.330 |
Why?
|
| Adiposity | 8 | 2017 | 1892 | 0.330 |
Why?
|
| Vasculitis | 1 | 2013 | 528 | 0.320 |
Why?
|
| Body Weight | 6 | 2019 | 4626 | 0.320 |
Why?
|
| Aryldialkylphosphatase | 1 | 2009 | 64 | 0.320 |
Why?
|
| Drug Prescriptions | 4 | 2024 | 1663 | 0.320 |
Why?
|
| Haptoglobins | 3 | 2015 | 166 | 0.320 |
Why?
|
| Eggs | 1 | 2010 | 182 | 0.320 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2008 | 538 | 0.320 |
Why?
|
| Dietary Fiber | 3 | 2022 | 767 | 0.310 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 686 | 0.310 |
Why?
|
| Appendicitis | 2 | 2012 | 680 | 0.310 |
Why?
|
| Survival Rate | 15 | 2021 | 12825 | 0.310 |
Why?
|
| Genetic Association Studies | 7 | 2019 | 2746 | 0.310 |
Why?
|
| Lipoprotein Lipase | 1 | 2009 | 133 | 0.310 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2023 | 3250 | 0.310 |
Why?
|
| Young Adult | 24 | 2024 | 59939 | 0.300 |
Why?
|
| Primary Health Care | 4 | 2016 | 4735 | 0.300 |
Why?
|
| Leukocyte Count | 3 | 2014 | 1606 | 0.300 |
Why?
|
| Internal Medicine | 4 | 2017 | 1064 | 0.300 |
Why?
|
| Interleukin-6 | 4 | 2019 | 3227 | 0.290 |
Why?
|
| Lipoproteins, LDL | 4 | 2022 | 642 | 0.290 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2008 | 488 | 0.290 |
Why?
|
| Drinking | 1 | 2009 | 196 | 0.290 |
Why?
|
| Registries | 10 | 2024 | 8351 | 0.290 |
Why?
|
| Weather | 1 | 2009 | 234 | 0.290 |
Why?
|
| Alcoholic Intoxication | 2 | 2018 | 171 | 0.290 |
Why?
|
| Serum Amyloid P-Component | 1 | 2007 | 46 | 0.280 |
Why?
|
| Acculturation | 1 | 2009 | 179 | 0.280 |
Why?
|
| Cholesterol, LDL | 6 | 2022 | 2392 | 0.280 |
Why?
|
| Mental Health | 4 | 2018 | 3270 | 0.280 |
Why?
|
| Inflammation Mediators | 4 | 2017 | 1889 | 0.280 |
Why?
|
| Internship and Residency | 6 | 2018 | 5943 | 0.280 |
Why?
|
| Cost of Illness | 2 | 2017 | 1949 | 0.280 |
Why?
|
| Opioid-Related Disorders | 3 | 2024 | 2188 | 0.280 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2024 | 564 | 0.280 |
Why?
|
| American Heart Association | 2 | 2022 | 1049 | 0.280 |
Why?
|
| Intensive Care Units | 5 | 2016 | 3799 | 0.270 |
Why?
|
| Patient Admission | 4 | 2016 | 1364 | 0.270 |
Why?
|
| Retirement | 2 | 2006 | 198 | 0.270 |
Why?
|
| Wit and Humor as Topic | 1 | 2006 | 31 | 0.270 |
Why?
|
| Hand Strength | 2 | 2021 | 464 | 0.270 |
Why?
|
| Brain | 7 | 2020 | 27159 | 0.270 |
Why?
|
| Gene Frequency | 8 | 2016 | 3624 | 0.270 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2021 | 398 | 0.260 |
Why?
|
| Amyloid beta-Peptides | 1 | 2020 | 3887 | 0.260 |
Why?
|
| Life Expectancy | 3 | 2023 | 1249 | 0.260 |
Why?
|
| Defibrillators, Implantable | 1 | 2016 | 1499 | 0.260 |
Why?
|
| Disease Progression | 13 | 2021 | 13640 | 0.260 |
Why?
|
| Alcohol-Induced Disorders | 1 | 2006 | 27 | 0.260 |
Why?
|
| Denmark | 3 | 2024 | 777 | 0.260 |
Why?
|
| Platelet Count | 1 | 2008 | 784 | 0.260 |
Why?
|
| Gait | 2 | 2024 | 823 | 0.250 |
Why?
|
| Prothrombin | 2 | 2016 | 194 | 0.250 |
Why?
|
| Sodium, Dietary | 4 | 2024 | 426 | 0.250 |
Why?
|
| Seasons | 2 | 2020 | 1521 | 0.250 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2012 | 1065 | 0.250 |
Why?
|
| End Stage Liver Disease | 2 | 2021 | 369 | 0.250 |
Why?
|
| Communication Barriers | 1 | 2009 | 418 | 0.250 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 2 | 2018 | 157 | 0.250 |
Why?
|
| Alanine Transaminase | 3 | 2015 | 608 | 0.240 |
Why?
|
| Sunburn | 1 | 2006 | 156 | 0.240 |
Why?
|
| Faculty, Medical | 3 | 2016 | 1226 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2016 | 6512 | 0.240 |
Why?
|
| Bone Remodeling | 2 | 2019 | 577 | 0.240 |
Why?
|
| Medical Order Entry Systems | 1 | 2010 | 523 | 0.240 |
Why?
|
| Flavonols | 2 | 2023 | 84 | 0.240 |
Why?
|
| Neurofilament Proteins | 2 | 2024 | 335 | 0.240 |
Why?
|
| Albumins | 2 | 2014 | 578 | 0.240 |
Why?
|
| Walking | 1 | 2012 | 1201 | 0.240 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2015 | 856 | 0.240 |
Why?
|
| Adolescent | 21 | 2024 | 88904 | 0.240 |
Why?
|
| Codeine | 1 | 2024 | 52 | 0.230 |
Why?
|
| Weight Gain | 5 | 2019 | 2356 | 0.230 |
Why?
|
| Epidemiologic Methods | 4 | 2019 | 1326 | 0.230 |
Why?
|
| Urinalysis | 3 | 2024 | 369 | 0.230 |
Why?
|
| Sleep | 4 | 2018 | 4815 | 0.230 |
Why?
|
| Veterans | 4 | 2012 | 2667 | 0.230 |
Why?
|
| Diabetic Angiopathies | 4 | 2015 | 806 | 0.230 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2022 | 530 | 0.230 |
Why?
|
| Educational Status | 5 | 2021 | 2510 | 0.230 |
Why?
|
| Kidney | 6 | 2021 | 7074 | 0.230 |
Why?
|
| Substance-Related Disorders | 4 | 2017 | 4421 | 0.230 |
Why?
|
| Medication Errors | 1 | 2010 | 784 | 0.230 |
Why?
|
| Chi-Square Distribution | 8 | 2017 | 3432 | 0.230 |
Why?
|
| Motor Activity | 4 | 2013 | 2711 | 0.230 |
Why?
|
| Retrospective Studies | 30 | 2021 | 81635 | 0.220 |
Why?
|
| Self Report | 6 | 2024 | 3771 | 0.220 |
Why?
|
| Echocardiography | 5 | 2018 | 5037 | 0.220 |
Why?
|
| Health Status Disparities | 1 | 2015 | 1880 | 0.220 |
Why?
|
| Frail Elderly | 3 | 2021 | 781 | 0.220 |
Why?
|
| Marijuana Abuse | 1 | 2008 | 409 | 0.220 |
Why?
|
| Warfarin | 3 | 2008 | 1494 | 0.220 |
Why?
|
| Isoleucine | 1 | 2023 | 111 | 0.220 |
Why?
|
| Health Care Costs | 1 | 2017 | 3242 | 0.220 |
Why?
|
| Informed Consent | 2 | 2018 | 1010 | 0.220 |
Why?
|
| Severity of Illness Index | 11 | 2021 | 15908 | 0.220 |
Why?
|
| Ketone Bodies | 1 | 2023 | 76 | 0.220 |
Why?
|
| Brain Diseases | 2 | 2004 | 1552 | 0.220 |
Why?
|
| Models, Statistical | 3 | 2014 | 5091 | 0.220 |
Why?
|
| Switzerland | 1 | 2024 | 322 | 0.220 |
Why?
|
| Fats, Unsaturated | 1 | 2023 | 21 | 0.210 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 2039 | 0.210 |
Why?
|
| Double-Blind Method | 9 | 2021 | 12430 | 0.210 |
Why?
|
| Sex Distribution | 7 | 2018 | 2274 | 0.210 |
Why?
|
| Self Disclosure | 1 | 2004 | 248 | 0.210 |
Why?
|
| Sorbitol | 1 | 2023 | 61 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2020 | 10384 | 0.210 |
Why?
|
| Biometry | 1 | 2006 | 571 | 0.210 |
Why?
|
| Fatty Liver | 2 | 2021 | 810 | 0.210 |
Why?
|
| Aspartate Aminotransferases | 2 | 2015 | 416 | 0.210 |
Why?
|
| Morbidity | 2 | 2020 | 1754 | 0.210 |
Why?
|
| Echocardiography, Doppler | 3 | 2018 | 899 | 0.210 |
Why?
|
| Endothelium, Vascular | 3 | 2024 | 4424 | 0.210 |
Why?
|
| Quercetin | 1 | 2023 | 97 | 0.200 |
Why?
|
| Waist Circumference | 4 | 2021 | 934 | 0.200 |
Why?
|
| Cholesterol | 3 | 2023 | 2903 | 0.200 |
Why?
|
| Platelet Aggregation | 1 | 2005 | 769 | 0.200 |
Why?
|
| Hematinics | 2 | 2024 | 282 | 0.200 |
Why?
|
| Sodium | 5 | 2024 | 1594 | 0.200 |
Why?
|
| Dilatation | 2 | 2021 | 311 | 0.200 |
Why?
|
| Lipase | 2 | 2018 | 320 | 0.200 |
Why?
|
| Regression Analysis | 4 | 2014 | 6329 | 0.200 |
Why?
|
| Leucine | 1 | 2023 | 547 | 0.200 |
Why?
|
| Anticholesteremic Agents | 2 | 2006 | 970 | 0.200 |
Why?
|
| Menstrual Cycle | 2 | 2022 | 539 | 0.200 |
Why?
|
| Platelet Activation | 1 | 2005 | 643 | 0.190 |
Why?
|
| Formularies as Topic | 1 | 2002 | 93 | 0.190 |
Why?
|
| Blood Proteins | 2 | 2024 | 1194 | 0.190 |
Why?
|
| Edema | 2 | 2016 | 764 | 0.190 |
Why?
|
| Valine | 1 | 2023 | 410 | 0.190 |
Why?
|
| New York | 1 | 2024 | 879 | 0.190 |
Why?
|
| Lipoprotein(a) | 3 | 2021 | 489 | 0.190 |
Why?
|
| Ethics, Clinical | 1 | 2002 | 101 | 0.190 |
Why?
|
| Solvents | 1 | 2003 | 299 | 0.190 |
Why?
|
| Hospitals | 6 | 2020 | 3888 | 0.190 |
Why?
|
| Boston | 7 | 2023 | 9346 | 0.190 |
Why?
|
| Mass Screening | 1 | 2017 | 5454 | 0.190 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2001 | 68 | 0.190 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 2059 | 0.190 |
Why?
|
| Personal Satisfaction | 1 | 2006 | 642 | 0.190 |
Why?
|
| Suicide, Attempted | 1 | 2010 | 1413 | 0.190 |
Why?
|
| Maternal Age | 1 | 2024 | 804 | 0.190 |
Why?
|
| Clinical Competence | 4 | 2018 | 4858 | 0.190 |
Why?
|
| 4-Butyrolactone | 1 | 2021 | 60 | 0.190 |
Why?
|
| Up-Regulation | 6 | 2016 | 4142 | 0.180 |
Why?
|
| Kupffer Cells | 1 | 2021 | 143 | 0.180 |
Why?
|
| Homozygote | 2 | 2016 | 1775 | 0.180 |
Why?
|
| Eye Diseases | 1 | 2007 | 660 | 0.180 |
Why?
|
| Proteomics | 3 | 2024 | 3914 | 0.180 |
Why?
|
| Menarche | 1 | 2024 | 532 | 0.180 |
Why?
|
| Electronic Health Records | 4 | 2024 | 4880 | 0.180 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2023 | 267 | 0.180 |
Why?
|
| Myocardial Revascularization | 2 | 2016 | 795 | 0.180 |
Why?
|
| Dietary Supplements | 5 | 2019 | 3429 | 0.180 |
Why?
|
| Headache | 1 | 2009 | 1260 | 0.180 |
Why?
|
| Cadmium | 1 | 2022 | 219 | 0.180 |
Why?
|
| Autocrine Communication | 1 | 2021 | 168 | 0.180 |
Why?
|
| Pilot Projects | 6 | 2025 | 8728 | 0.180 |
Why?
|
| Lignans | 1 | 2021 | 83 | 0.180 |
Why?
|
| Reproducibility of Results | 12 | 2024 | 20144 | 0.180 |
Why?
|
| Glucuronates | 1 | 2020 | 40 | 0.180 |
Why?
|
| Survival Analysis | 8 | 2016 | 10100 | 0.180 |
Why?
|
| Osmolar Concentration | 1 | 2021 | 655 | 0.180 |
Why?
|
| Forearm | 1 | 2023 | 425 | 0.180 |
Why?
|
| Autonomic Nervous System | 2 | 2022 | 707 | 0.170 |
Why?
|
| Methylamines | 1 | 2021 | 136 | 0.170 |
Why?
|
| Peer Review, Health Care | 2 | 2016 | 73 | 0.170 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 1055 | 0.170 |
Why?
|
| Estradiol | 2 | 2025 | 1947 | 0.170 |
Why?
|
| Digital Rectal Examination | 1 | 2020 | 42 | 0.170 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2023 | 539 | 0.170 |
Why?
|
| Diet Records | 3 | 2016 | 425 | 0.170 |
Why?
|
| Lisinopril | 1 | 2020 | 60 | 0.170 |
Why?
|
| Confidence Intervals | 5 | 2012 | 2921 | 0.170 |
Why?
|
| Down-Regulation | 3 | 2018 | 2931 | 0.170 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2021 | 109 | 0.170 |
Why?
|
| Paracrine Communication | 1 | 2021 | 277 | 0.170 |
Why?
|
| Factor VII | 2 | 2015 | 139 | 0.170 |
Why?
|
| Food-Processing Industry | 1 | 2019 | 14 | 0.170 |
Why?
|
| Nurses | 4 | 2017 | 2503 | 0.170 |
Why?
|
| Tobacco Use Disorder | 1 | 2006 | 708 | 0.170 |
Why?
|
| Urine | 1 | 2021 | 363 | 0.170 |
Why?
|
| Atrophy | 2 | 2004 | 1631 | 0.170 |
Why?
|
| Palmitic Acid | 3 | 2015 | 148 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2006 | 2258 | 0.170 |
Why?
|
| Medical Audit | 4 | 2002 | 454 | 0.170 |
Why?
|
| Pulmonary Embolism | 3 | 2024 | 2596 | 0.170 |
Why?
|
| Disability Evaluation | 2 | 2018 | 1827 | 0.170 |
Why?
|
| Thoracic Vertebrae | 1 | 2024 | 613 | 0.170 |
Why?
|
| Caffeine | 1 | 2004 | 702 | 0.160 |
Why?
|
| Oleic Acids | 1 | 2019 | 71 | 0.160 |
Why?
|
| Energy Intake | 2 | 2020 | 2142 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2023 | 1852 | 0.160 |
Why?
|
| Central Venous Pressure | 2 | 2016 | 80 | 0.160 |
Why?
|
| Adenosine Deaminase | 1 | 2021 | 253 | 0.160 |
Why?
|
| MicroRNAs | 1 | 2015 | 3792 | 0.160 |
Why?
|
| Language | 1 | 2009 | 1550 | 0.160 |
Why?
|
| Food Industry | 1 | 2019 | 68 | 0.160 |
Why?
|
| Ferritins | 1 | 2022 | 601 | 0.160 |
Why?
|
| Attitude to Health | 1 | 2008 | 2021 | 0.160 |
Why?
|
| Counseling | 1 | 2007 | 1552 | 0.160 |
Why?
|
| Probability | 3 | 2016 | 2476 | 0.160 |
Why?
|
| alpha-Tocopherol | 1 | 2019 | 127 | 0.160 |
Why?
|
| Nonlinear Dynamics | 2 | 2018 | 490 | 0.160 |
Why?
|
| Hemostasis | 1 | 2001 | 467 | 0.160 |
Why?
|
| Haplotypes | 4 | 2016 | 2727 | 0.160 |
Why?
|
| Anthocyanins | 2 | 2023 | 80 | 0.160 |
Why?
|
| Interviews as Topic | 4 | 2015 | 2741 | 0.150 |
Why?
|
| Renal Replacement Therapy | 1 | 2021 | 282 | 0.150 |
Why?
|
| Coronary Angiography | 6 | 2018 | 4508 | 0.150 |
Why?
|
| Insulin-Secreting Cells | 3 | 2015 | 899 | 0.150 |
Why?
|
| Anticoagulants | 4 | 2024 | 4855 | 0.150 |
Why?
|
| Hyperglycemia | 4 | 2016 | 1389 | 0.150 |
Why?
|
| Caloric Restriction | 1 | 2021 | 303 | 0.150 |
Why?
|
| Mitral Valve | 2 | 2017 | 1473 | 0.150 |
Why?
|
| Insurance Coverage | 2 | 2022 | 1945 | 0.150 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2019 | 94 | 0.150 |
Why?
|
| Diuresis | 1 | 2018 | 107 | 0.150 |
Why?
|
| Metoprolol | 1 | 2018 | 90 | 0.150 |
Why?
|
| Tauopathies | 1 | 2022 | 325 | 0.150 |
Why?
|
| Cognition Disorders | 4 | 2014 | 3967 | 0.150 |
Why?
|
| Premature Birth | 3 | 2021 | 1830 | 0.150 |
Why?
|
| Prescription Drugs | 2 | 2024 | 634 | 0.150 |
Why?
|
| Ramipril | 1 | 2018 | 102 | 0.150 |
Why?
|
| Motivation | 1 | 2008 | 2020 | 0.150 |
Why?
|
| Regional Blood Flow | 1 | 2021 | 1478 | 0.150 |
Why?
|
| Iatrogenic Disease | 5 | 2002 | 551 | 0.150 |
Why?
|
| Income | 1 | 2006 | 1875 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 3 | 2019 | 1733 | 0.150 |
Why?
|
| Dietary Carbohydrates | 1 | 2023 | 896 | 0.150 |
Why?
|
| Stearic Acids | 2 | 2014 | 56 | 0.150 |
Why?
|
| Menopause | 2 | 2024 | 1657 | 0.150 |
Why?
|
| Stroke Volume | 5 | 2023 | 5618 | 0.150 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 622 | 0.140 |
Why?
|
| Asymptomatic Diseases | 2 | 2018 | 588 | 0.140 |
Why?
|
| Flavonoids | 2 | 2023 | 447 | 0.140 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2017 | 326 | 0.140 |
Why?
|
| Apolipoprotein A-I | 1 | 2019 | 305 | 0.140 |
Why?
|
| Referral and Consultation | 2 | 2022 | 3618 | 0.140 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 473 | 0.140 |
Why?
|
| Neoplasms | 7 | 2024 | 22350 | 0.140 |
Why?
|
| Intestinal Perforation | 1 | 2019 | 254 | 0.140 |
Why?
|
| Nutritional Status | 2 | 2021 | 1621 | 0.140 |
Why?
|
| Potassium, Dietary | 2 | 2014 | 103 | 0.140 |
Why?
|
| Marfan Syndrome | 1 | 2019 | 237 | 0.140 |
Why?
|
| Matched-Pair Analysis | 2 | 2009 | 285 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2013 | 3459 | 0.140 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 1998 | 132 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 10745 | 0.140 |
Why?
|
| Rheumatic Diseases | 1 | 2024 | 658 | 0.140 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 3 | 2024 | 253 | 0.140 |
Why?
|
| Extremities | 1 | 2002 | 869 | 0.140 |
Why?
|
| Apolipoproteins B | 2 | 2021 | 385 | 0.140 |
Why?
|
| Folic Acid | 2 | 2014 | 1337 | 0.140 |
Why?
|
| Linoleic Acid | 2 | 2021 | 158 | 0.140 |
Why?
|
| Risk-Taking | 1 | 2022 | 1021 | 0.130 |
Why?
|
| Orthostatic Intolerance | 1 | 2016 | 22 | 0.130 |
Why?
|
| Firearms | 3 | 2009 | 630 | 0.130 |
Why?
|
| Water-Electrolyte Balance | 2 | 2015 | 326 | 0.130 |
Why?
|
| Prediabetic State | 1 | 2022 | 547 | 0.130 |
Why?
|
| Professional Review Organizations | 5 | 2002 | 48 | 0.130 |
Why?
|
| Placebos | 2 | 2014 | 1659 | 0.130 |
Why?
|
| Feasibility Studies | 4 | 2021 | 5306 | 0.130 |
Why?
|
| Vitamin K Deficiency | 1 | 2016 | 24 | 0.130 |
Why?
|
| Medical Records | 4 | 2004 | 1408 | 0.130 |
Why?
|
| Pulsatile Flow | 1 | 2017 | 318 | 0.130 |
Why?
|
| Drug Utilization | 1 | 2002 | 1187 | 0.130 |
Why?
|
| Hospital Mortality | 4 | 2020 | 5343 | 0.130 |
Why?
|
| Phenotype | 8 | 2024 | 16724 | 0.130 |
Why?
|
| Interprofessional Relations | 1 | 2002 | 998 | 0.130 |
Why?
|
| Dental Plaque | 1 | 2017 | 214 | 0.130 |
Why?
|
| Hepatitis, Chronic | 1 | 2016 | 53 | 0.130 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2019 | 399 | 0.130 |
Why?
|
| Osteoporosis | 2 | 2024 | 1581 | 0.130 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2017 | 416 | 0.130 |
Why?
|
| Treatment Outcome | 9 | 2020 | 65273 | 0.130 |
Why?
|
| Body Weights and Measures | 1 | 2016 | 208 | 0.130 |
Why?
|
| Receptors, Estrogen | 1 | 2024 | 2251 | 0.130 |
Why?
|
| Systole | 2 | 2017 | 935 | 0.130 |
Why?
|
| Tooth Loss | 1 | 2017 | 198 | 0.120 |
Why?
|
| Naloxone | 1 | 2018 | 372 | 0.120 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 2418 | 0.120 |
Why?
|
| Social Support | 2 | 2023 | 2191 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 1 | 2024 | 1089 | 0.120 |
Why?
|
| Glucose Intolerance | 1 | 2019 | 578 | 0.120 |
Why?
|
| Sigmoidoscopy | 1 | 2015 | 150 | 0.120 |
Why?
|
| Sickness Impact Profile | 1 | 2016 | 299 | 0.120 |
Why?
|
| Massachusetts | 5 | 2016 | 8891 | 0.120 |
Why?
|
| Meat Products | 1 | 2015 | 97 | 0.120 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2016 | 350 | 0.120 |
Why?
|
| Ammonia | 1 | 2016 | 245 | 0.120 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 2 | 2013 | 152 | 0.120 |
Why?
|
| Sweetening Agents | 1 | 2017 | 291 | 0.120 |
Why?
|
| Fruit | 2 | 2023 | 1166 | 0.120 |
Why?
|
| Apolipoprotein E4 | 3 | 2019 | 709 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2002 | 1512 | 0.120 |
Why?
|
| Air Pollution | 1 | 2009 | 2391 | 0.120 |
Why?
|
| Uric Acid | 1 | 2021 | 809 | 0.120 |
Why?
|
| Vegetables | 2 | 2022 | 1199 | 0.120 |
Why?
|
| Coffea | 1 | 2014 | 22 | 0.120 |
Why?
|
| Linkage Disequilibrium | 4 | 2013 | 1996 | 0.120 |
Why?
|
| Erythrocytes | 2 | 2014 | 2412 | 0.120 |
Why?
|
| Leisure Activities | 1 | 2016 | 310 | 0.120 |
Why?
|
| Age of Onset | 5 | 2013 | 3342 | 0.120 |
Why?
|
| Poverty | 2 | 2022 | 2714 | 0.120 |
Why?
|
| Creatine Kinase | 3 | 2003 | 683 | 0.120 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2021 | 1657 | 0.110 |
Why?
|
| Dental Plaque Index | 1 | 2014 | 96 | 0.110 |
Why?
|
| Gingival Crevicular Fluid | 1 | 2014 | 96 | 0.110 |
Why?
|
| Periodontal Index | 1 | 2014 | 149 | 0.110 |
Why?
|
| Neuropsychological Tests | 4 | 2020 | 7119 | 0.110 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 1197 | 0.110 |
Why?
|
| Medically Uninsured | 1 | 2019 | 838 | 0.110 |
Why?
|
| Femur | 1 | 2020 | 1318 | 0.110 |
Why?
|
| Periodontal Pocket | 1 | 2014 | 174 | 0.110 |
Why?
|
| Ticlopidine | 1 | 1998 | 730 | 0.110 |
Why?
|
| Liver Function Tests | 1 | 2015 | 527 | 0.110 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2015 | 110 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2020 | 935 | 0.110 |
Why?
|
| Proteome | 1 | 2024 | 1894 | 0.110 |
Why?
|
| Information Dissemination | 1 | 2022 | 1142 | 0.110 |
Why?
|
| Drug Substitution | 1 | 2016 | 292 | 0.110 |
Why?
|
| Hip Joint | 1 | 2020 | 1017 | 0.110 |
Why?
|
| Riboflavin | 1 | 2014 | 106 | 0.110 |
Why?
|
| Snoring | 1 | 2015 | 210 | 0.110 |
Why?
|
| Self-Assessment | 1 | 2016 | 400 | 0.110 |
Why?
|
| Vitamin D | 3 | 2023 | 3270 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 939 | 0.110 |
Why?
|
| Psychotherapy | 1 | 2022 | 1648 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2019 | 3804 | 0.110 |
Why?
|
| alpha-Linolenic Acid | 2 | 2011 | 145 | 0.110 |
Why?
|
| Terrorism | 1 | 2016 | 211 | 0.110 |
Why?
|
| Diuretics | 2 | 2015 | 614 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2021 | 36567 | 0.110 |
Why?
|
| Thyroid Gland | 1 | 2020 | 1170 | 0.110 |
Why?
|
| Carotid Arteries | 1 | 2017 | 932 | 0.110 |
Why?
|
| Documentation | 1 | 2019 | 914 | 0.110 |
Why?
|
| Diabetic Retinopathy | 2 | 2013 | 1300 | 0.100 |
Why?
|
| Epistasis, Genetic | 1 | 2015 | 353 | 0.100 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2019 | 889 | 0.100 |
Why?
|
| Lipogenesis | 1 | 2014 | 217 | 0.100 |
Why?
|
| Vaginal Smears | 1 | 2015 | 505 | 0.100 |
Why?
|
| Primary Prevention | 2 | 2023 | 1188 | 0.100 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 8717 | 0.100 |
Why?
|
| Minority Groups | 1 | 2020 | 1208 | 0.100 |
Why?
|
| Diet Surveys | 3 | 2012 | 1159 | 0.100 |
Why?
|
| Telomere | 1 | 2019 | 943 | 0.100 |
Why?
|
| Thyroid Nodule | 1 | 2020 | 765 | 0.100 |
Why?
|
| Pre-Eclampsia | 1 | 2022 | 1256 | 0.100 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2022 | 1188 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 1 | 2021 | 1168 | 0.100 |
Why?
|
| Apolipoprotein B-100 | 1 | 2013 | 157 | 0.100 |
Why?
|
| Glucuronidase | 1 | 2014 | 205 | 0.100 |
Why?
|
| Hyperinsulinism | 1 | 2015 | 402 | 0.100 |
Why?
|
| Pericardium | 1 | 2017 | 681 | 0.100 |
Why?
|
| Meat | 1 | 2015 | 588 | 0.100 |
Why?
|
| Analgesics, Opioid | 3 | 2024 | 3837 | 0.100 |
Why?
|
| Health | 1 | 2015 | 397 | 0.100 |
Why?
|
| Calcium Channel Blockers | 2 | 2019 | 687 | 0.100 |
Why?
|
| Lectins | 1 | 2014 | 490 | 0.100 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2016 | 881 | 0.100 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 682 | 0.100 |
Why?
|
| Endarterectomy, Carotid | 1 | 2017 | 556 | 0.100 |
Why?
|
| Vitamin B 6 | 1 | 2013 | 237 | 0.100 |
Why?
|
| Monocytes | 1 | 2021 | 2600 | 0.100 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2001 | 1251 | 0.100 |
Why?
|
| Forecasting | 1 | 2021 | 2936 | 0.100 |
Why?
|
| Carbohydrate Metabolism | 1 | 2012 | 261 | 0.100 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2014 | 263 | 0.100 |
Why?
|
| Long QT Syndrome | 1 | 2016 | 473 | 0.100 |
Why?
|
| Brain Infarction | 2 | 2021 | 284 | 0.090 |
Why?
|
| Tonsillitis | 1 | 2011 | 28 | 0.090 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 1078 | 0.090 |
Why?
|
| Histamine H2 Antagonists | 1 | 2013 | 168 | 0.090 |
Why?
|
| Trace Elements | 1 | 2013 | 193 | 0.090 |
Why?
|
| Sarcopenia | 1 | 2016 | 378 | 0.090 |
Why?
|
| Photoperiod | 1 | 2012 | 141 | 0.090 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2011 | 951 | 0.090 |
Why?
|
| Exercise Tolerance | 1 | 2016 | 847 | 0.090 |
Why?
|
| Population Groups | 1 | 2012 | 209 | 0.090 |
Why?
|
| Likelihood Functions | 1 | 2014 | 993 | 0.090 |
Why?
|
| Leukocytes | 1 | 2019 | 2035 | 0.090 |
Why?
|
| Fibronectins | 1 | 2014 | 722 | 0.090 |
Why?
|
| Research Design | 1 | 2006 | 6207 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2018 | 7868 | 0.090 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2014 | 278 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 1 | 2020 | 2463 | 0.090 |
Why?
|
| Migraine Disorders | 2 | 2016 | 1710 | 0.090 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2011 | 300 | 0.090 |
Why?
|
| Pregnancy | 8 | 2024 | 30237 | 0.090 |
Why?
|
| Vitamin A | 1 | 2013 | 611 | 0.090 |
Why?
|
| Tachycardia, Ventricular | 3 | 2006 | 1313 | 0.090 |
Why?
|
| Polypharmacy | 1 | 2013 | 307 | 0.090 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 14652 | 0.090 |
Why?
|
| Postoperative Period | 3 | 2014 | 1824 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 6307 | 0.080 |
Why?
|
| Memory | 1 | 2020 | 2192 | 0.080 |
Why?
|
| Aftercare | 1 | 2016 | 915 | 0.080 |
Why?
|
| Ascorbic Acid | 1 | 2013 | 658 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 1935 | 0.080 |
Why?
|
| Fats | 1 | 2010 | 99 | 0.080 |
Why?
|
| Alleles | 6 | 2019 | 6895 | 0.080 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2010 | 77 | 0.080 |
Why?
|
| Hepatitis C, Chronic | 1 | 2018 | 1033 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2019 | 1241 | 0.080 |
Why?
|
| Coronary Vessels | 3 | 2016 | 3100 | 0.080 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2016 | 1093 | 0.080 |
Why?
|
| Muscle, Skeletal | 2 | 2021 | 4970 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2019 | 2693 | 0.080 |
Why?
|
| Adaptation, Physiological | 1 | 2016 | 1313 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2016 | 2425 | 0.080 |
Why?
|
| Air Pressure | 1 | 2009 | 75 | 0.080 |
Why?
|
| Drug Users | 1 | 2011 | 134 | 0.080 |
Why?
|
| Phosphates | 1 | 2013 | 763 | 0.080 |
Why?
|
| Diastole | 1 | 2011 | 784 | 0.080 |
Why?
|
| Kidney Calculi | 1 | 2013 | 458 | 0.080 |
Why?
|
| Longevity | 3 | 2022 | 1083 | 0.080 |
Why?
|
| Vitamin E | 1 | 2013 | 872 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 1612 | 0.080 |
Why?
|
| Sulfur Dioxide | 1 | 2009 | 178 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 4652 | 0.080 |
Why?
|
| Plant Preparations | 1 | 2009 | 93 | 0.080 |
Why?
|
| Anthropometry | 1 | 2013 | 1336 | 0.080 |
Why?
|
| Polymorphism, Genetic | 3 | 2007 | 4249 | 0.080 |
Why?
|
| Social Class | 3 | 2016 | 2007 | 0.080 |
Why?
|
| Cacao | 1 | 2009 | 98 | 0.080 |
Why?
|
| Aorta | 1 | 2016 | 2043 | 0.080 |
Why?
|
| Oxidative Stress | 2 | 2017 | 3139 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 1026 | 0.080 |
Why?
|
| Osteocalcin | 2 | 2019 | 271 | 0.070 |
Why?
|
| Age Distribution | 4 | 2016 | 2869 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2014 | 1469 | 0.070 |
Why?
|
| Humidity | 1 | 2009 | 206 | 0.070 |
Why?
|
| Tonsillectomy | 1 | 2011 | 281 | 0.070 |
Why?
|
| Health Policy | 1 | 2020 | 2698 | 0.070 |
Why?
|
| Central Nervous System Depressants | 1 | 2008 | 163 | 0.070 |
Why?
|
| Poisoning | 1 | 2009 | 254 | 0.070 |
Why?
|
| Software | 2 | 2021 | 4466 | 0.070 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2017 | 1087 | 0.070 |
Why?
|
| Arteries | 1 | 2012 | 1123 | 0.070 |
Why?
|
| Appendectomy | 1 | 2011 | 445 | 0.070 |
Why?
|
| Homeostasis | 2 | 2023 | 3342 | 0.070 |
Why?
|
| Colonoscopy | 1 | 2015 | 1409 | 0.070 |
Why?
|
| Curriculum | 2 | 2018 | 3783 | 0.070 |
Why?
|
| Adipose Tissue | 2 | 2017 | 3314 | 0.070 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 1120 | 0.070 |
Why?
|
| Netherlands | 3 | 2020 | 2277 | 0.070 |
Why?
|
| Marital Status | 1 | 2008 | 426 | 0.070 |
Why?
|
| Fishes | 1 | 2010 | 607 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 3485 | 0.070 |
Why?
|
| Cholesterol, VLDL | 1 | 2007 | 70 | 0.070 |
Why?
|
| Hippocampus | 1 | 2020 | 3776 | 0.070 |
Why?
|
| Residence Characteristics | 4 | 2012 | 2116 | 0.070 |
Why?
|
| Mental Recall | 1 | 2013 | 1218 | 0.070 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2007 | 113 | 0.070 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 2221 | 0.070 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2010 | 565 | 0.070 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1998 | 2763 | 0.070 |
Why?
|
| Demography | 2 | 2001 | 1641 | 0.070 |
Why?
|
| Alcoholism | 3 | 2014 | 1980 | 0.070 |
Why?
|
| Spinal Fractures | 1 | 2013 | 702 | 0.070 |
Why?
|
| Air Pollutants, Occupational | 1 | 2009 | 406 | 0.070 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 2355 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2024 | 20708 | 0.070 |
Why?
|
| Aortic Valve | 1 | 2016 | 1966 | 0.070 |
Why?
|
| Holidays | 1 | 2006 | 41 | 0.070 |
Why?
|
| Telemedicine | 1 | 2024 | 3111 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 811 | 0.060 |
Why?
|
| Population Surveillance | 2 | 2013 | 2594 | 0.060 |
Why?
|
| Databases, Factual | 5 | 2021 | 8066 | 0.060 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2015 | 1104 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 3 | 2000 | 1804 | 0.060 |
Why?
|
| Hip | 1 | 2007 | 251 | 0.060 |
Why?
|
| Cardiotonic Agents | 1 | 2008 | 541 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2018 | 3070 | 0.060 |
Why?
|
| Collagen Type I | 2 | 2019 | 616 | 0.060 |
Why?
|
| Carbon | 1 | 2009 | 673 | 0.060 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 3927 | 0.060 |
Why?
|
| Femur Neck | 1 | 2007 | 316 | 0.060 |
Why?
|
| Integrin beta3 | 1 | 2005 | 120 | 0.060 |
Why?
|
| Models, Biological | 2 | 2015 | 9461 | 0.060 |
Why?
|
| Data Collection | 1 | 2014 | 3321 | 0.060 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 1897 | 0.060 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 2023 | 0.060 |
Why?
|
| Evidence-Based Medicine | 2 | 2010 | 3692 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2013 | 1217 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2014 | 3641 | 0.060 |
Why?
|
| Mammography | 1 | 2015 | 2429 | 0.060 |
Why?
|
| Lipid Metabolism | 3 | 2023 | 1895 | 0.060 |
Why?
|
| Sphygmomanometers | 1 | 2024 | 20 | 0.060 |
Why?
|
| Adenosine Diphosphate | 1 | 2005 | 421 | 0.060 |
Why?
|
| International Normalized Ratio | 1 | 2006 | 382 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2013 | 1303 | 0.060 |
Why?
|
| Mood Disorders | 1 | 2011 | 1127 | 0.060 |
Why?
|
| Animals | 9 | 2020 | 168930 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2014 | 2694 | 0.060 |
Why?
|
| Ventricular Fibrillation | 1 | 2006 | 538 | 0.060 |
Why?
|
| Circadian Rhythm | 3 | 2014 | 2593 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2016 | 2416 | 0.060 |
Why?
|
| Antithrombin III | 1 | 2024 | 128 | 0.060 |
Why?
|
| Bariatric Surgery | 1 | 2014 | 996 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 566 | 0.050 |
Why?
|
| Clinical Clerkship | 2 | 2017 | 569 | 0.050 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2008 | 463 | 0.050 |
Why?
|
| Postoperative Complications | 5 | 2017 | 15831 | 0.050 |
Why?
|
| Connecticut | 5 | 2002 | 365 | 0.050 |
Why?
|
| Sulfonylurea Compounds | 1 | 2005 | 220 | 0.050 |
Why?
|
| Saphenous Vein | 1 | 2006 | 519 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 6550 | 0.050 |
Why?
|
| Factor VIIa | 1 | 2024 | 103 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2018 | 3681 | 0.050 |
Why?
|
| P-Selectin | 1 | 2005 | 598 | 0.050 |
Why?
|
| Carbonated Beverages | 1 | 2004 | 209 | 0.050 |
Why?
|
| Obesity, Morbid | 1 | 2014 | 1292 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3110 | 0.050 |
Why?
|
| Students, Medical | 1 | 2016 | 1962 | 0.050 |
Why?
|
| Nursing Audit | 1 | 2002 | 13 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3232 | 0.050 |
Why?
|
| Ventricular Remodeling | 2 | 2023 | 1281 | 0.050 |
Why?
|
| Physicians | 3 | 2017 | 4591 | 0.050 |
Why?
|
| Urban Population | 1 | 2010 | 2040 | 0.050 |
Why?
|
| Adolescent Behavior | 1 | 2011 | 1184 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2016 | 14471 | 0.050 |
Why?
|
| Temperature | 1 | 2009 | 2233 | 0.050 |
Why?
|
| Epinephrine | 1 | 2005 | 782 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2008 | 956 | 0.050 |
Why?
|
| Follicular Phase | 1 | 2002 | 143 | 0.050 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2021 | 64 | 0.050 |
Why?
|
| Cytokines | 2 | 2014 | 7438 | 0.050 |
Why?
|
| Genomics | 2 | 2014 | 5923 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 3230 | 0.050 |
Why?
|
| Blood Coagulation Factors | 1 | 2004 | 371 | 0.050 |
Why?
|
| Automobile Driving | 1 | 2007 | 442 | 0.050 |
Why?
|
| Lymphocyte Subsets | 1 | 2022 | 313 | 0.050 |
Why?
|
| Oxygen | 1 | 2013 | 4251 | 0.050 |
Why?
|
| Acute Disease | 4 | 2011 | 7241 | 0.050 |
Why?
|
| Limbic System | 1 | 2004 | 418 | 0.050 |
Why?
|
| Pharmacists | 1 | 2024 | 261 | 0.050 |
Why?
|
| Blood Viscosity | 1 | 2001 | 125 | 0.050 |
Why?
|
| Thrombin | 1 | 2024 | 600 | 0.050 |
Why?
|
| Family Health | 1 | 2006 | 1254 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2006 | 1419 | 0.050 |
Why?
|
| Suicidal Ideation | 1 | 2011 | 1467 | 0.050 |
Why?
|
| Antithrombins | 1 | 2024 | 294 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 2846 | 0.050 |
Why?
|
| Nova Scotia | 1 | 2020 | 33 | 0.050 |
Why?
|
| United States Environmental Protection Agency | 1 | 2021 | 139 | 0.050 |
Why?
|
| Sex Characteristics | 2 | 2016 | 2645 | 0.050 |
Why?
|
| Algorithms | 5 | 2024 | 14072 | 0.050 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2015 | 325 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2006 | 6214 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2016 | 3276 | 0.040 |
Why?
|
| Sentinel Surveillance | 2 | 2002 | 292 | 0.040 |
Why?
|
| Carotid Artery, Common | 1 | 2021 | 172 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2021 | 254 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2001 | 279 | 0.040 |
Why?
|
| Molecular Weight | 2 | 2012 | 2168 | 0.040 |
Why?
|
| Anxiety | 2 | 2019 | 4670 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8735 | 0.040 |
Why?
|
| Finland | 1 | 2001 | 608 | 0.040 |
Why?
|
| Water Pollutants, Chemical | 1 | 2024 | 356 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 7431 | 0.040 |
Why?
|
| Fibrinolysis | 1 | 2001 | 331 | 0.040 |
Why?
|
| Water Supply | 1 | 2021 | 204 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 7871 | 0.040 |
Why?
|
| Reference Values | 1 | 2007 | 4913 | 0.040 |
Why?
|
| Depressive Disorder | 3 | 2014 | 3715 | 0.040 |
Why?
|
| Physical Examination | 1 | 2006 | 1265 | 0.040 |
Why?
|
| Medical Record Linkage | 1 | 2021 | 286 | 0.040 |
Why?
|
| California | 5 | 2002 | 1435 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2019 | 25 | 0.040 |
Why?
|
| Employment | 1 | 2006 | 1110 | 0.040 |
Why?
|
| Reproduction | 1 | 2024 | 645 | 0.040 |
Why?
|
| Cardiovascular Agents | 2 | 2021 | 849 | 0.040 |
Why?
|
| Mass Vaccination | 1 | 2021 | 111 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 8621 | 0.040 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 13485 | 0.040 |
Why?
|
| Adrenergic Agents | 1 | 2019 | 72 | 0.040 |
Why?
|
| Live Birth | 1 | 2023 | 516 | 0.040 |
Why?
|
| Temperance | 2 | 2010 | 88 | 0.040 |
Why?
|
| Family Relations | 1 | 2001 | 318 | 0.040 |
Why?
|
| Temperament | 1 | 2001 | 300 | 0.040 |
Why?
|
| Kidney Function Tests | 2 | 2012 | 685 | 0.040 |
Why?
|
| Prescriptions | 1 | 2021 | 388 | 0.040 |
Why?
|
| Niacinamide | 1 | 2020 | 419 | 0.040 |
Why?
|
| Nitroglycerin | 1 | 2019 | 332 | 0.040 |
Why?
|
| beta Carotene | 1 | 2019 | 523 | 0.040 |
Why?
|
| Troponin T | 1 | 2023 | 786 | 0.040 |
Why?
|
| Infertility | 1 | 2024 | 655 | 0.040 |
Why?
|
| Database Management Systems | 1 | 1999 | 263 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2001 | 680 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2018 | 507 | 0.040 |
Why?
|
| Erythropoiesis | 1 | 2021 | 692 | 0.040 |
Why?
|
| Schizophrenia | 1 | 2016 | 6976 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2009 | 1936 | 0.040 |
Why?
|
| Frontal Lobe | 1 | 2004 | 1408 | 0.040 |
Why?
|
| Genetic Markers | 2 | 2014 | 2603 | 0.040 |
Why?
|
| Office Visits | 1 | 2021 | 593 | 0.030 |
Why?
|
| Skull | 1 | 2021 | 819 | 0.030 |
Why?
|
| Collagen | 1 | 2005 | 2635 | 0.030 |
Why?
|
| Drugs, Generic | 1 | 2002 | 457 | 0.030 |
Why?
|
| Particulate Matter | 1 | 2009 | 2635 | 0.030 |
Why?
|
| Hepatic Encephalopathy | 1 | 2018 | 143 | 0.030 |
Why?
|
| Mentors | 1 | 2002 | 671 | 0.030 |
Why?
|
| Italy | 1 | 2018 | 856 | 0.030 |
Why?
|
| Ischemia | 1 | 2005 | 1905 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 428 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2018 | 482 | 0.030 |
Why?
|
| Cerebellum | 1 | 2004 | 1520 | 0.030 |
Why?
|
| Keratin-18 | 1 | 2016 | 37 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 739 | 0.030 |
Why?
|
| Ascites | 1 | 2018 | 336 | 0.030 |
Why?
|
| Flavones | 1 | 2016 | 66 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 5789 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 1377 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2016 | 367 | 0.030 |
Why?
|
| Flavanones | 1 | 2016 | 75 | 0.030 |
Why?
|
| Solubility | 1 | 2017 | 1078 | 0.030 |
Why?
|
| Knowledge | 1 | 2017 | 178 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2006 | 6020 | 0.030 |
Why?
|
| Ohio | 1 | 2016 | 320 | 0.030 |
Why?
|
| Electronic Mail | 1 | 2017 | 215 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2001 | 1164 | 0.030 |
Why?
|
| Eicosanoic Acids | 1 | 2015 | 15 | 0.030 |
Why?
|
| Mice | 3 | 2016 | 81889 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2002 | 1791 | 0.030 |
Why?
|
| Rabbits | 1 | 2001 | 4752 | 0.030 |
Why?
|
| Androgens | 1 | 2022 | 1280 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2014 | 68 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 1131 | 0.030 |
Why?
|
| Child | 4 | 2016 | 80668 | 0.030 |
Why?
|
| Twins, Dizygotic | 1 | 2015 | 236 | 0.030 |
Why?
|
| New England | 1 | 2017 | 1059 | 0.030 |
Why?
|
| Bone Resorption | 1 | 2018 | 721 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2002 | 949 | 0.030 |
Why?
|
| Epilepsy | 1 | 2009 | 3317 | 0.030 |
Why?
|
| Quality of Health Care | 2 | 2016 | 4306 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 3266 | 0.030 |
Why?
|
| Resistin | 1 | 2014 | 174 | 0.030 |
Why?
|
| Television | 1 | 2016 | 409 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2014 | 2902 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2002 | 2053 | 0.030 |
Why?
|
| Twins, Monozygotic | 1 | 2015 | 471 | 0.030 |
Why?
|
| Pulmonary Edema | 1 | 2016 | 409 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 2018 | 591 | 0.030 |
Why?
|
| Fragaria | 1 | 2013 | 21 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 949 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2006 | 2390 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2016 | 677 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2014 | 472 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2018 | 962 | 0.030 |
Why?
|
| Consensus | 1 | 2022 | 3208 | 0.020 |
Why?
|
| TRPM Cation Channels | 1 | 2013 | 139 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2015 | 520 | 0.020 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2012 | 110 | 0.020 |
Why?
|
| Thrombosis | 1 | 2005 | 2953 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2016 | 1156 | 0.020 |
Why?
|
| Polysomnography | 1 | 2018 | 1868 | 0.020 |
Why?
|
| Specialization | 1 | 2016 | 779 | 0.020 |
Why?
|
| Patient Care | 1 | 2017 | 629 | 0.020 |
Why?
|
| Illinois | 1 | 2011 | 120 | 0.020 |
Why?
|
| Heart Conduction System | 1 | 2016 | 1007 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2018 | 1343 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 246 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2014 | 606 | 0.020 |
Why?
|
| Immunoassay | 1 | 2014 | 742 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2011 | 368 | 0.020 |
Why?
|
| Afghan Campaign 2001- | 1 | 2012 | 298 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2017 | 1259 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2011 | 246 | 0.020 |
Why?
|
| Sports | 1 | 2016 | 701 | 0.020 |
Why?
|
| Mother-Child Relations | 1 | 2014 | 498 | 0.020 |
Why?
|
| Time | 1 | 2012 | 550 | 0.020 |
Why?
|
| Oximetry | 1 | 2013 | 461 | 0.020 |
Why?
|
| Angina Pectoris | 2 | 2004 | 956 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2013 | 654 | 0.020 |
Why?
|
| Causality | 1 | 2016 | 1252 | 0.020 |
Why?
|
| Social Change | 1 | 2010 | 152 | 0.020 |
Why?
|
| Indians, North American | 1 | 2013 | 354 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2016 | 2351 | 0.020 |
Why?
|
| Glycosylation | 1 | 2013 | 1099 | 0.020 |
Why?
|
| Career Choice | 1 | 2016 | 768 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 2078 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2024 | 4554 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1999 | 4188 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 11920 | 0.020 |
Why?
|
| Environment | 1 | 2015 | 1120 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 11094 | 0.020 |
Why?
|
| Adipokines | 1 | 2011 | 308 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2016 | 1865 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2021 | 26389 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2024 | 3850 | 0.020 |
Why?
|
| Mexico | 1 | 2011 | 770 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 1794 | 0.020 |
Why?
|
| Metagenomics | 1 | 2012 | 473 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2019 | 2744 | 0.020 |
Why?
|
| ROC Curve | 1 | 2016 | 3620 | 0.020 |
Why?
|
| Organ Size | 1 | 2013 | 2261 | 0.020 |
Why?
|
| Stilbenes | 1 | 2008 | 155 | 0.020 |
Why?
|
| Learning | 1 | 2017 | 1754 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2018 | 2559 | 0.020 |
Why?
|
| Emergency Medicine | 1 | 2017 | 1220 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2016 | 2504 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2009 | 297 | 0.020 |
Why?
|
| Peptides | 1 | 2019 | 4344 | 0.020 |
Why?
|
| Parents | 1 | 2001 | 3593 | 0.020 |
Why?
|
| Heart Atria | 1 | 2013 | 1361 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2010 | 779 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2016 | 42577 | 0.020 |
Why?
|
| Lead Poisoning | 1 | 2009 | 318 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2008 | 521 | 0.020 |
Why?
|
| Education | 1 | 2009 | 531 | 0.020 |
Why?
|
| Hypoglycemic Agents | 2 | 2012 | 3108 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 3430 | 0.020 |
Why?
|
| Patient Selection | 1 | 2018 | 4252 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 6850 | 0.020 |
Why?
|
| Lung | 1 | 2024 | 10067 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2012 | 1756 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2015 | 1516 | 0.010 |
Why?
|
| Emotions | 1 | 2016 | 2758 | 0.010 |
Why?
|
| Quantitative Trait Loci | 1 | 2012 | 2136 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2008 | 1206 | 0.010 |
Why?
|
| Sepsis | 1 | 2016 | 2604 | 0.010 |
Why?
|
| Recurrence | 1 | 2013 | 8507 | 0.010 |
Why?
|
| Antioxidants | 1 | 2008 | 1671 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 7475 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2008 | 2141 | 0.010 |
Why?
|
| Judgment | 1 | 2001 | 270 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 8045 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 2002 | 350 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 22352 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 2002 | 602 | 0.010 |
Why?
|
| Random Allocation | 1 | 2000 | 2394 | 0.010 |
Why?
|
| Disease | 1 | 2000 | 675 | 0.010 |
Why?
|
| Health Services Research | 1 | 2002 | 1811 | 0.010 |
Why?
|
| Infant | 1 | 2016 | 36461 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 2000 | 1547 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 1998 | 1432 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2011 | 6869 | 0.010 |
Why?
|